PALO
ALTO, Calif., March 26,
2024 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq:
KOD), a biopharmaceutical company committed to researching,
developing and commercializing transformative therapeutics to treat
high prevalence retinal diseases, announced today that it will
report fourth quarter and full-year 2023 financial results on
Thursday, March 28, 2024. Management
will host a conference call and live webcast to discuss recent
business highlights and provide a corporate update at 4:30 p.m. Eastern Time on March 28, 2024.
To access the webcast, please register
at https://edge.media-server.com/mmc/p/q4jdxku4/.
A live audio webcast of the event will be available on the
"Events and Presentations" section of Kodiak's Investors &
Media website at http://ir.kodiak.com/. A replay of the webcast
will be available for a limited time following the event.
About Kodiak Sciences
Inc.
Kodiak Sciences ("we," the "Company" or "Kodiak") (Nasdaq: KOD)
is a biopharmaceutical company committed to researching, developing
and commercializing transformative therapeutics to treat a broad
spectrum of retinal diseases. We are focused on bringing new
science to the design and manufacture of next generation retinal
medicines to prevent and treat the leading causes of blindness
globally. Our ABC Platform™ uses molecular engineering to merge the
fields of protein-based and chemistry-based therapies and has been
at the core of Kodiak's discovery engine. We are developing a
portfolio of three late-stage clinical programs, two of which are
derived from our ABC Platform and one which is
platform-independent.
Kodiak's lead investigational medicine, tarcocimab, is a novel
anti-VEGF antibody biopolymer conjugate under development for the
treatment of high prevalence retinal vascular diseases including
diabetic retinopathy, the leading cause of blindness in working-age
patients in the developed world, and wet age-related macular
degeneration, the leading cause of blindness in elderly patients in
the developed world.
KSI-501 is our second investigational medicine, a first-in-class
anti-IL-6, VEGF-trap bispecific antibody biopolymer conjugate
designed to inhibit both IL-6 mediated inflammation and
VEGF-mediated angiogenesis and vascular permeability. KSI-501 is
being developed for the treatment of high prevalence retinal
vascular diseases to address the unmet needs of targeting multiple
biologies and extended durability.
Additionally, Kodiak is developing a third product candidate,
KSI-101, a novel anti-IL-6, VEGF-trap bispecific protein, the
unconjugated protein portion of KSI-501. Kodiak intends to develop
KSI-101 for the treatment of retinal inflammatory diseases, as
currently there are no available intravitreal biologic therapies
addressing the spectrum of inflammatory conditions of the
retina.
Kodiak has expanded its early research pipeline of duet and
triplet inhibitors that embed small molecules and other bioactive
molecules in the biopolymer backbone to provide a high
drug-antibody ratio ("DAR"). The diverse bioactives are designed to
be released over time to achieve sustained inhibition of targeted
biological pathways. We believe this unique combination of high DAR
and extended therapeutic benefit offers potential for broad and
important utility for multifactorial ophthalmic and systemic
diseases.
For more information, please visit www.kodiak.com.
Kodiak®, Kodiak Sciences®, ABC™, ABC Platform™ and the Kodiak
logo are registered trademarks or trademarks of Kodiak Sciences
Inc. in various global jurisdictions.
Forward-Looking
Statements
This release contains "forward-looking statements" within the
meaning of Section 27A of the Securities Act of 1933, Section 21E
of the Securities Exchange Act of 1934 and the Private Securities
Litigation Reform Act of 1995. These forward-looking statements are
not based on historical fact and include statements regarding: the
potential of our ABC Platform; the potential for our duet and
triplet inhibitors to provide broad and important utility
for multifactorial ophthalmic and systemic diseases; and
intended development plans. Forward-looking statements generally
include statements that are predictive in nature and depend upon or
refer to future events or conditions, and include words such as
"may," "will," "should," "would," "could," "expect," "plan,"
"believe," "intend," "pursue," and other similar expressions among
others. Any forward-looking statements are based on management's
current expectations of future events and are subject to a risks
and uncertainties that could cause actual results to differ
materially and adversely from those in or implied by such
forward-looking statements. These risks and uncertainties include,
but are not limited to: the risk that our ABC Platform and/or our
duet and triplet inhibitors may not provide the benefits or
function in the manner anticipated, or at all; cessation or delay
of any clinical studies and/or development
of tarcocimab , KSI-501 and/or KSI-101 may occur; adverse
economic conditions may significantly impact our business and
operations, including our clinical trial sites, and those of our
manufacturers, contract research organizations or others with whom
we conduct business; as well as the other risks identified in our
filings with the Securities and Exchange
Commission (SEC). For a discussion of other risks and
uncertainties, and other important factors, any of which could
cause our actual results to differ from those contained in the
forward-looking statements, see the section entitled "Risk Factors"
in our most recent Form 10-K, as well as discussions of potential
risks, uncertainties, and other important factors in our subsequent
filings with the SEC. These forward-looking statements speak
only as of the date hereof and Kodiak undertakes no obligation to
update forward-looking statements, and readers are cautioned not to
place undue reliance on such forward-looking statements.
View original
content:https://www.prnewswire.com/news-releases/kodiak-sciences-to-report-fourth-quarter-and-full-year-2023-financial-results-and-host-business-updates-webcast-on-march-28-2024-302098792.html
SOURCE Kodiak Sciences Inc.